Pakistan Journal of Nuclear Medicine

Not available Continue Reading

Novel targeted therapies tailored to the molecular profile of tumors have revolutionized the treatment landscape for advanced radioiodine-refractory differentiated thyroid cancer (RAI-R DTC), showcasing notable progression-free survival rates. These emerging therapies, leveraging kinase inhibitors, exhibit a remarkable capacity to restore iodide uptake in RAI-R thyroid cancer cells. However, successful implementation... Continue Reading

Radioactive iodine therapy is non-invasive, well established and effective treatment for hyperthyroidism. However, there are concerns about its potential to cause thyroid cancer when used for benign thyroid diseases. While studies show mixed results, our observations indicate that the risk of cancer after RAI therapy for benign conditions is very... Continue Reading

This commentary delves into the significance of molecular markers, specifically BRAF and TERT mutations, in refining risk stratification and management strategies for thyroid cancer, with a focus on optimizing radioactive iodine (RAI) doses. BRAFV600E mutation notably impacts risk classification in papillary thyroid cancer (PTC), elevating it to intermediate-risk status and... Continue Reading

Background: Thyroid cancer recurrence poses a significant challenge in oncology, necessitating effective tools for early prediction. Machine learning models offer the potential to improve prognostic accuracy and guide clinical decision-making. Aim and Objective: This study aims to investigate the efficacy of machine learning models in predicting thyroid cancer recurrence using... Continue Reading